Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250023/S002

Allurion Gastric Balloon System

Allurion Technologies, Inc. · Decision date Sep 23, 2026

MEDTECHLEDGER EXPLANATIONP250023/S002

What did the FDA approve?

The FDA database entry records an approval decision, dated 2026-09-23, for supplement P250023/S002 to PMA P250023, the Allurion Gastric Balloon System. The supplement type is the Normal 180 Day Track No User Fee, and the stated reason is a postapproval study protocol. The applicant is Allurion Technologies, Inc. The device falls under product code LTI in the category implant, intragastric for morbid obesity, within Gastroenterology, Urology.

The source statement identifies the changed item as the revised protocol for the post-approval study Allurion Gastric Balloon PAS. The announcement of the revised protocol does not by itself establish safety or clinical effectiveness of the device. The entry does not describe protocol content, study endpoints, patient numbers, or trial results; those details are absent from the supplied fields. It does not grant a new approval of the whole system.

FDA approval order statement

the revised protocol for the post-approval study (PAS) Allurion Gastric Balloon PAS
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Gastroenterology, Urology
Decision date
Sep 23, 2026
FDA change category
Postapproval Study Protocol

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250023/S002
Regulatory pathway
PMA supplement
Product code
LTI
Decision code
APPR
Decision date
Sep 23, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: IMPLANT, INTRAGASTRIC FOR MORBID OBESITY.

Product code
LTI
FDA device class
3

For the original device and its historical approval scope, see PMA P250023. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250023 · Original PMA

    Allurion Gastric Balloon System

  2. P250023/S002 received

    Application receipt date recorded by FDA.

  3. P250023/S001 · Related supplement

    Allurion Gastric Balloon System

  4. P250023/S002 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P250023. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250023

Product / regulatory recordCompanyPathwayDecision dateSource
Allurion Technologies, Inc.PMA approvalFeb 20, 2026FDA
Allurion Technologies, Inc.PMA supplementSep 9, 2026FDA

Explore the linked device profile

Other records with product code LTI

Product / regulatory recordCompanyPathwayDecision dateSource
BOSTON SCIENTIFIC CORPORATIONPMA supplementJan 5, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Allurion Technologies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
11 Huron Dr., Natick, MA, 01760

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records